Associate Professor Carolyn Day

Associate Professor
Addiction Medicine, Central Clinical School

Telephone +61 2 9515 8817

Map

Biographical details

A/Prof Day is a public health researcher in drug and alcohol, with a focus on illicit drug use. She is an investigator on numerous research projects involving epidemiological, behavioural, qualitative and clinical research techniques and methods and collaborated widely across disciplines and institutions.

A/Prof completed her PhD at the National Drug and Alcohol Research Centre and was awarded NHMRC post-doctorate fellowship which she undertook at the Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research) before mobbing to Sydney Medical School. A/Prof Day coordinates Addiction Medicine education for the Sydney Medical School and is co-editor of a leading Addiction Medicine text used. She is also Deputy-Postgraduate Coordinator for Sydney Central Clinical School.

A/Prof Day has been a Director of the NSW Alcohol and Drug Foundation (ADF NSW) since 2009 and the Vice President since 2012 which a residential treatment service for women with substance use issues and their children. She is also an Honorary Research Associate with the Sydney Uniting Medically Supervised Injecting Centre and a member of the Sydney Local Health District Harm Minimisation Program Steering Committee.

Research interests

Women and substance use, including substance use in pregnancy and parenting, especially policies and practices

Illicit drug use, especially harm reduction and prevention programs

Social determinants of health and programs which improve these form marginalised populations

Teaching and supervision

I have coordinated addiction medicine education in the Sydney Medical Program since 2007 and coorindate the unit of study "Alcohol, Drug and Health" (PUBH5114/5).

Selected grants

2017

  • Health Justice Partnership - Evaluation of legal intervention on health outcomes; Day C; Sydney Local Health District/Research Support.

2011

  • Factors influencing pharmacy services in opiod substitution programs; Day C, Chaar B, Fois R, Hanrahan J; Health Administration Corporation/Research Support.
  • Unmet healthcare needs and barriers to healthcare utilisation of young Aboriginal drug users in inner city Sydney: a pilot study; Conigrave K, Day C; Health Administration Corporation/Drug and Alcohol Research Grant.

2010

  • LNK transfer: NHMRC partnership project 'Evaluation of a Model for Assessment and Treatment of Hepat; Day C, Miszczak E, Hirshorn J.

2007

  • The impact of injecting patterns and drug dependence treatment on hepatitis C treatment outcomes for injecting drug users; Day C; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Day, C. (2015). Public health responses to drug and alcohol use. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), Addiction Medicine: Principles and Practice, (pp. 36-47). Melbourne: IP Communications.
  • Reid, S., Day, C. (2015). Women and drugs. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), Addiction Medicine: Principles and Practice, (pp. 379-387). Melbourne: IP Communications.
  • Day, C., Haber, P. (2009). Managing drug dependence in people with hepatitis C. In G. Dore, M. Temple-Smith, A. Lloyd (Eds.), Hepatitis C: An Expanding Perspective, (pp. 288-307). East Hawthorn, Victoria: IP Communications.

Journals

  • Ezard, N., Cecilio, M., Clifford, B., Baldry, E., Burns, L., Day, C., Shanahan, M., Dolan, K. (2018). A managed alcohol program in Sydney, Australia: Acceptability, cost-savings and non-beverage alcohol use. Drug and Alcohol Review, 37(Suppl. 1), S184-S194. [More Information]
  • Kovitwanichkanont, T., Day, C. (2018). Prescription Opioid Misuse and Public Health Approach in Australia. Substance Use and Misuse, 53(2), 200-205. [More Information]
  • Spaulding, A., Eldridge, G., Chico, C., Morisseau, N., Drobeniuc, A., Fils-Aime, R., Day, C., Hopkins, R., Jin, X., Chen, J., et al (2018). Smoking in Correctional Settings Worldwide: Prevalence, Bans, and Interventions. Epidemiologic Reviews, 40(1), 82-95. [More Information]
  • Day, C., Coupland, H., Moensted, M., Burns, L. (2018). The need for more research and considered debate regarding women's only treatment services: a comment on Neale et al 2018. Addiction, 113(9), 1752. [More Information]
  • Reid, S., Day, C., Bowen, D., Minnis, J., Ludlow, J., Jacobs, S., Gordon, A., Haber, P. (2018). Vertical transmission of hepatitis C: Testing and health-care engagement. Journal of Paediatrics and Child Health, 54(6), 647-652. [More Information]
  • Fortier, E., Alavi, M., Bruneau, J., Micallef, M., Perram, J., Sockalingam, S., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Haber, P., et al (2017). Depression, Anxiety, and Stress among People with Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 11(1), 10-18. [More Information]
  • Larney, S., Hickman, M., Guy, R., Grebely, J., Dore, G., Gray, R., Day, C., Kimber, J., Degenhardt, L. (2017). Estimating the number of people who inject drugs in Australia. BMC Public Health, 17(757), 1-7. [More Information]
  • Butler, K., Day, C., Sutherland, R., van Buskirk, J., Breen, C., Burns, L., Larney, S. (2017). Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. International Journal of Drug Policy, 47, 102-106. [More Information]
  • Al-Ansari, B., Day, C., Thow, A., Conigrave, K. (2016). Civil alcohol policy in Muslim majority countries: need for global tools, expert support and local partnerships. Addiction, 111(10), 1718-1719. [More Information]
  • White, B., Haber, P., Day, C. (2016). Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia. International Journal of Drug Policy, 27, 121-126. [More Information]
  • Day, C., Shanahan, M., Wand, H., Topp, L., Haber, P., Rodgers, C., Deacon, R., Walsh, N., Kaldor, J., Van Beek, I., et al (2016). Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. Journal Of Clinical Virology, 74, 66-72. [More Information]
  • Al-Ansari, B., Thow, A., Day, C., Conigrave, K. (2016). Extent of alcohol prohibition in civil policy in Muslim majority countries: the impact of globalization. Addiction, 111(10), 1703-1713. [More Information]
  • Mitchell, S., Bungay, V., Day, C., Mooney-Somers, J. (2016). Has the experience of Hepatitis C diagnosis improved over the last decade? An analysis of Canadian women's experiences. The Canadian Journal of Nursing Research, 48(1), 21-28. [More Information]
  • Black, K., Day, C. (2016). Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy Among Women with Substance Use Disorders. Substance Abuse: Research and Treatment, 10(Suppl. 1), 27-33. [More Information]
  • Heyes, C., Schofield, T., Gribble, R., Day, C., Haber, P. (2016). Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study. Transplantation Direct, 2(10), 1-9. [More Information]
  • Day, C., White, B., Haber, P. (2016). The impact of an automatic syringe dispensing machine in inner-city Sydney, Australia: No evidence of a 'honey-pot' effect. Drug and Alcohol Review, 35(5), 637-643. [More Information]
  • Stirling, R., Day, C. (2016). The policy and practices of New South Wales drug treatment providers in responding to the possession of illicit substances on premises. Drug and Alcohol Review, 35(5), 644-649. [More Information]
  • Grebely, J., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Phung, N., Weltman, M., Day, C., Treloar, C., Bath, N., Haber, P., et al (2016). Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study. Addiction, 111(2), 311-319. [More Information]
  • Keats, J., Micallef, M., Grebely, J., Hazelwood, S., Everingham, H., Hazelwood, S., Jones, T., Bath, N., Treloar, C., Dore, G., et al (2015). Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy, 26(10), 999-1006. [More Information]
  • Alavi, M., Micallef, M., Fortier, E., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G., et al (2015). Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study. Journal of Viral Hepatitis, 22(11), 914-925. [More Information]
  • Treloar, C., Rance, J., Bath, N., Everingham, H., Micallef, M., Day, C., Hazelwood, S., Grebely, J., Dore, G. (2015). Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy, 26(10), 992-998. [More Information]
  • Haber, P., Day, C., Topp, L., Shanahan, M., Wand, H., van Beek, I., Maher, L. (2015). Hepatitis B vaccination for people who inject drugs. The Lancet, 385(9963), 115. [More Information]
  • Alavi, M., Spelman, T., Matthews, G., Haber, P., Day, C., Van Beek, I., Walsh, N., Yeung, B., Bruneau, J., Petoumenos, K., et al (2015). Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 26(10), 976-983. [More Information]
  • Fowler, C., Rossiter, C., Sherwood, J., Day, C. (2015). New Understandings of Mothering: Mothers in an Abstinence-Based Drug Treatment Program. International Journal of Mental Health and Addiction, 13(2), 173-184. [More Information]
  • Bui, J., Day, C., Hanrahan, J., Winstock, A., Chaar, B. (2015). Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. Drug and Alcohol Review, 34(5), 495-498. [More Information]
  • Fortier, E., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G., et al (2015). The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 26(11), 1094-1102. [More Information]
  • Butler, K., Day, C., Dietze, P., Bruno, R., Alati, R., Burns, L. (2015). The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia. Journal of Substance Abuse Treatment, 58, 90-94. [More Information]
  • Fowler, C., Reid, S., Minnis, J., Day, C. (2014). Experiences of mothers with substance dependence: Informing the development of parenting support. Journal of Clinical Nursing, 23(19-20), 2835-2843. [More Information]
  • Deacon, R., Hines, S., Curry, K., Tynan, M., Day, C. (2014). Feasibility of ambulatory withdrawal management delivered in a NSW drug health service and correlates of completion. Australian Health Review, 38(2), 186-189. [More Information]
  • Shand, F., Day, C., Rawlinson, W., Degenhardt, L., Martin, N., Nelson, E. (2014). Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. Australian and New Zealand Journal of Public Health, 38(2), 160-164. [More Information]
  • Haber, P., Day, C. (2014). Overview of Substance Use and Treatment from Australia. Substance Abuse, 35(3), 304-308. [More Information]
  • Islam, M., Conigrave, K., Day, C., Nguyen, Y., Haber, P. (2014). Twenty-year trends in benzodiazepine dispensing in the Australian population. Internal Medicine Journal, 44(1), 57-64. [More Information]
  • Topp, L., Day, C., Wand, H., Deacon, R., Van Beek, I., Haber, P., Shanahan, M., Rodgers, C., Maher, L. (2013). A randomised controlled trial of �?nancial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine, 57(4), 297-303. [More Information]
  • Islam, M., Topp, L., Conigrave, K., White, A., Haber, P., Day, C. (2013). Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. International Journal of Drug Policy, 24(4), 326-332. [More Information]
  • Alavi, M., Grebely, J., Micallef, M., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G. (2013). Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. Clinical Infectious Diseases, 57(Suppl 2), S62-S69. [More Information]
  • Md Mofizul, M., Topp, L., Conigrave, K., Day, C. (2013). De�?ning a service for people who use drugs as 'low-threshold': What should be the criteria? International Journal of Drug Policy, 24(3), 220-222. [More Information]
  • Chaar, B., Wang, H., Day, C., Hanrahan, J., Winstock, A., Fois, R. (2013). Factors influencing pharmacy services in opioid substitution treatment. Drug and Alcohol Review, 32(4), 426-434. [More Information]
  • Islam, M., Taylor, A., Smyth, C., Day, C. (2013). General health of opioid substitution therapy clients. Internal Medicine Journal, 43(12), 1335-1338. [More Information]
  • Islam, M., Topp, L., Iversen, J., Day, C., Conigrave, K., Maher, L. (2013). Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs. Australian and New Zealand Journal of Public Health, 37(2), 148-154. [More Information]
  • Islam, M., Topp, L., Conigrave, K., Day, C. (2013). Opioid substitution therapy clients' preferences for targeted versus general primary health-care outlets. Drug and Alcohol Review, 32(2), 211-214. [More Information]
  • Topp, L., Islam, M., Day, C. (2013). Relative efficacy of cash versus vouchers in engaging opioid substitution treatment clients in survey-based research. Journal of Medical Ethics, 39(4), 253-256. [More Information]
  • Mofizul Islam, M., Day, C., Conigrave, K., Topp, L. (2013). Self-perceived problem with alcohol use among opioid substitution treatment clients. Addictive Behaviors, 38(4), 2018-2021. [More Information]
  • Islam, M., Topp, L., Conigrave, K., Haber, P., White, A., Day, C. (2013). Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Australian and New Zealand Journal of Public Health, 37(4), 311-315. [More Information]
  • Islam, M., Shanahan, M., Topp, L., Conigrave, K., White, A., Day, C. (2013). The cost of providing primary health-care services from a needle and syringe program: A case study. Drug and Alcohol Review, 32(3), 312-319. [More Information]
  • Deacon, R., Topp, L., Wand, H., Day, C., Rodgers, C., Haber, P., van Beek, I., Maher, L. (2012). Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. Journal of Urban Health, 89(5), 769-778. [More Information]
  • Alavi, M., Grebely, J., Matthews, G., Petoumenos, K., Yeung, B., Day, C., Lloyd, A., van Beek, I., Kaldor, J., Hellard, M., Haber, P., et al (2012). Effect of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 27(5), 957-965. [More Information]
  • Day, C., Demirkol, A., Tynan, M., Curry, K., Hines, S., Lintzeris, N., Haber, P. (2012). Individual versus team-based case-management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 31(4), 499-506. [More Information]
  • Islam, M., Topp, L., Conigrave, K., White, A., Reid, S., Grummett, S., Haber, P., Day, C. (2012). Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment, 43(4), 440-445. [More Information]
  • Mofizul Islam, M., Topp, L., Day, C., Dawson, A., Conigrave, K. (2012). Primary healthcare outlets that target injecting drug users: Opportunity to make services accessible and acceptable to the target group. International Journal of Drug Policy, 23(2), 109-110. [More Information]
  • Mofizul Islam, M., Topp, L., Day, C., Dawson, A., Conigrave, K. (2012). The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: A narrative synthesis of literature. International Journal of Drug Policy, 23(2), 94-102. [More Information]
  • Islam, M., Topp, L., Conigrave, K., van Beek, I., Maher, L., White, A., Rodgers, C., Day, C. (2012). The reliability of sensitive information provided by injecting drug users in a clinical setting: Clinician-administered versus audio computer-assisted self-interviewing (ACASI). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 24(12), 1496-1503. [More Information]
  • Mofizul Islam, M., Grummett, S., White, A., Reid, S., Day, C., Haber, P. (2011). A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. Australian and New Zealand Journal of Public Health, 35(3), 294-295. [More Information]
  • Day, C., Topp, L. (2011). Commentary on Turner et al. (2011): Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission. Addiction, 106(11), 1989-1990. [More Information]
  • Day, C., Mofizul Islam, M., White, A., Reid, S., Hayes, S., Haber, P. (2011). Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Australian Journal of Primary Health, 17(1), 10-15. [More Information]
  • Topp, L., Day, C., Iversen, J., Wand, H., Maher, L. (2011). Fifteen years of HIV surveillance among people who inject drugs: the Australian Needle and Syringe Program Survey 1995-2009. AIDS, 25(6), 835-842. [More Information]
  • Chaar, B., Hanrahan, J., Day, C. (2011). Provision of Opioid Substitution Therapy Services in Australian Pharmacies. Australasian Medical Journal, 4(4), 210-216. [More Information]
  • Sanson-Fisher, R., Brand, M., Shakeshaft, A., Haber, P., Day, C., Conigrave, K., Mattick, R., Lintzeris, N., Teesson, M. (2010). Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. Drug and Alcohol Review, 29(5), 469-474. [More Information]
  • Mofizul Islam, M., Day, C., Conigrave, K. (2010). Harm reduction healthcare: From an alternative to the mainstream platform? International Journal of Drug Policy, 21(2), 131-133. [More Information]
  • Day, C., White, B., Dore, G., van Beek, I., Rodgers, C., Cunningham, P., Wodak, A., Maher, L. (2010). Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status. Drug and Alcohol Dependence, 108(40210 (1-2)), 134-137. [More Information]
  • Dunn, M., Day, C., Bruno, R., Degenhardt, L., Campbell, G. (2010). Sexual and injecting risk behaviours among regular ecstasy users. Addictive Behaviors, 35(2), 157-160. [More Information]
  • Ramasamy, P., Lintzeris, N., Sutton, Y., Taylor, H., Day, C., Haber, P. (2010). The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 105(2), 329-334. [More Information]
  • Doab, A., Topp, L., Day, C., Dore, G., Maher, L. (2009). Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. Contemporary Clinical Trials, 30(5), 431-435. [More Information]
  • Topp, L., Day, C., Dore, G., Maher, L. (2009). Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review. Drug and Alcohol Review, 28(6), 669-675. [More Information]
  • Coupland, H., Day, C., Levy, M., Maher, L. (2009). Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users. Health Promotion Journal of Australia, 20(3), 234-240. [More Information]
  • White, B., Day, C., Thein, H., Doab, A., Bates, A., Holden, J., van Beek, I., Maher, L. (2008). Acceptability of hepatitis C virus testing methods among injecting drug users. Drug and Alcohol Review, 27, 666-670. [More Information]
  • Conroy, E., Kimber, J., Dolan, K., Day, C. (2008). An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia. Addiction Research and Theory, 16(6), 607-617. [More Information]
  • Day, C., Topp, L., Iversen, J., Maher, L., Australian NSPs, C. (2008). Blood-borne virus prevalence and risk among steroid injectors: Results from the Australian Needle and Syringe Program Survey. Drug and Alcohol Review, 27(5), 559-561. [More Information]
  • Day, C., White, B., Thein, H., Doab, A., Dore, G., Bates, A., Holden, J., Maher, L. (2008). Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 20(1), 116-123. [More Information]
  • O'Brien, S., Day, C., Black, E., Dolan, K. (2008). Injecting drug users' understanding of hepatitis C. Addictive Behaviors, 33(12), 1602-1605. [More Information]
  • Topp, L., Iversen, J., Wand, H., Day, C., Kaldor, J., Maher, L. (2008). Representativeness of Injecting Drug Users Who Participate in HIV Surveillance: Results From Australia's Needle and Syringe Program Survey. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 47(5), 632-638. [More Information]
  • White, B., Day, C., Maher, L. (2007). Self reported risk behaviour among injecting drug users: Self versus assisted questionnaire completion. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 19(3), 441-447. [More Information]
  • Day, C., Degenhardt, L., Hall, W. (2006). Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review, 25(4), 307-313. [More Information]
  • Day, C., Dolan, K. (2006). Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promotion Journal of Australia, 17(1), 70-72. [More Information]
  • Day, C., Degenhardt, L., Hall, W. (2006). Documenting the heroin shortage in New South Wales. Drug and Alcohol Review, 25(4), 297-305. [More Information]
  • Degenhardt, L., Day, C., Conroy, E., Gilmour, S. (2006). Examining Links Between Cocaine Use and Street-Based Sex Work in New South Wales, Australia. Journal of Sex Research, 43(2), 107-114. [More Information]
  • Gilmour, S., Koch, I., Degenhardt, L., Day, C. (2006). Identification and quantification of change in Australian illicit drug markets. BMC Public Health, 6, 200-1-200-10. [More Information]
  • Conroy, E., Degenhardt, L., Day, C. (2006). Impact of Drug Market Changes on Substance-Using Pregnant Women in Three Key Sydney Drug Markets. Women and Health: the multidisciplinary journal of women's health issues, 44(4), 93-105. [More Information]
  • Day, C., Nassirimanesh, B., Shakeshaft, A., Dolan, K. (2006). Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduction Journal, 3, 2-1-2-5. [More Information]
  • Day, C., Conroy, E., Lowe, J., Page, J., Dolan, K. (2006). Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health, 14(3), 120-125. [More Information]
  • White, B., Day, C., Degenhardt, L., Kinner, S., Fry, C., Bruno, R., Johnston, J. (2006). Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. Drug and Alcohol Dependence, 83(3), 210-217. [More Information]
  • Degenhardt, L., Day, C., Gilmour, S., Hall, W. (2006). The "lessons" of the Australian "heroin shortage". Substance Abuse Treatment, Prevention, and Policy, 1, 11-1-11-7. [More Information]
  • Gilmour, S., Degenhardt, L., Hall, W., Day, C. (2006). Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Medical Research Methodology, 6, 16-1-16-9. [More Information]
  • Degenhardt, L., Day, C., Conroy, E., Gilmour, S., Hall, W. (2005). Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage" in NSW, Australia. Drug and Alcohol Dependence, 79(3), 397-404. [More Information]
  • Degenhardt, L., Day, C., Dietze, P., Pointer, S., Conroy, E., Collins, L., Hall, W. (2005). Effects of a sustained heroin shortage in three Australian States. Addiction, 100(7), 908-920. [More Information]
  • Day, C., Ross, J., Dietze, P., Dolan, K. (2005). Initiation to heroin injecting among heroin users in Sydney, Australia: cross sectional survey. Harm Reduction Journal, 2, 2-1-2-7. [More Information]
  • Degenhardt, L., Hall, W., Day, C., Dietze, P., Collins, L., Pointer, S. (2005). Mapping the Consequences of an Unanticipated Drug Supply Change of Uncertain Origins: Response to the Commentaries. Addiction, 100(7), 930-932. [More Information]
  • Degenhardt, L., Day, C., Gilmour, S., Hall, W. (2005). Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy, 16(5), 300-307. [More Information]
  • Shakeshaft, A., Nassirimanesh, B., Day, C., Dolan, K. (2005). Perceptions of substance use, treatment options and training needs among Iranian primary care physicians. International Journal for Equity in Health, 4, 7-1-7-6. [More Information]
  • Gibson, A., Degenhardt, L., Day, C., McKetin, R. (2005). Recent trends in heroin supply to markets in Australia, the United States and Western Europe. International Journal of Drug Policy, 16(5), 293-299. [More Information]
  • Degenhardt, L., Conroy, E., Day, C., Gilmour, S., Hall, W. (2005). The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence, 79(2), 129-135. [More Information]
  • Day, C., Degenhardt, L., Gilmour, S., Hall, W. (2005). The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health, 5, 84-1-84-8. [More Information]
  • Gibson, A., Day, C., Degenhardt, L. (2005). The impact of illicit drug market changes on health agency operations in Sydney, Australia. Journal of Substance Abuse Treatment, 28(1), 35-40. [More Information]
  • Degenhardt, L., Day, C., Hall, W., Conroy, E., Gilmour, S. (2005). Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime? BMC Public Health, 5, 40-1-40-10. [More Information]
  • Southgate, E., Weatherall, A., Day, C., Dolan, K. (2005). What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal for Equity in Health, 4, 5-1-5-6. [More Information]
  • Day, C., Degenhardt, L., Gilmour, S., Hall, W. (2004). Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes. BMJ: British Medical Journal, 329(7463), 428-429. [More Information]
  • Day, C., Jayasuriya, R., Stone, G. (2004). Hepatitis C-related discriminationin New South Wales. Australian Health Review, 27(2), 57-60.
  • Day, C., Collins, L., Degenhardt, L., Thetford, C., Maher, L. (2004). Reliability of Heroin Users' Reports of Drug Use Behaviour Using a 24-Month Timeline-Follow-Back Technique to Assess the Impact of the Australian Heroin Shortage. Addiction Research and Theory, 12(5), 433-443. [More Information]
  • Lynskey, M., Day, C., Hall, W. (2003). Alcohol and other drug use disorders among older-aged people. Drug and Alcohol Review, 22(2), 125-133.
  • Topp, L., Day, C., Degenhardt, L. (2003). Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug and Alcohol Dependence, 70, 275-286. [More Information]
  • Day, C., Ross, J., Dolan, K. (2003). Characteristics of Aboriginal Injecting Drug Users in Sydney, Australia: Prison History, Hepatitis C Status and Drug Treatment Experiences. Journal of Ethnicity in Substance Abuse, 2(3), 51-58. [More Information]
  • Topp, L., Degenhardt, L., Day, C., Collins, L. (2003). Contemplating drug monitoring systems in the light of Australia's "heroin shortage" [Editorial]. Drug and Alcohol Review, 22(1), 3-6. [More Information]
  • Day, C., Topp, L., Rouen, D., Darke, S., Hall, W., Dolan, K. (2003). Decreased heroin availability in Sydney in early 2001. Addiction, 98(1), 93-95. [More Information]
  • Day, C., Ross, J., Dolan, K. (2003). Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug and Alcohol Review, 22(3), 317-321. [More Information]
  • Degenhardt, L., Topp, L., Day, C. (2003). Issues surrounding the detection of a reduction in drug supply: the heroin shortage in Australia in 2001. United Nations. Bulletin on Narcotics, 55(1-2), 131-140.
  • Day, C., White, B., Ross, J., Dolan, K. (2003). Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney [Letter]. Australian and New Zealand Journal of Public Health, 27(5), 558.
  • Day, C., Topp, L. (2003). Safety in drug and alcohol research [Editorial]. Addiction, 98(12), 1641-1643. [More Information]

2018

  • Ezard, N., Cecilio, M., Clifford, B., Baldry, E., Burns, L., Day, C., Shanahan, M., Dolan, K. (2018). A managed alcohol program in Sydney, Australia: Acceptability, cost-savings and non-beverage alcohol use. Drug and Alcohol Review, 37(Suppl. 1), S184-S194. [More Information]
  • Kovitwanichkanont, T., Day, C. (2018). Prescription Opioid Misuse and Public Health Approach in Australia. Substance Use and Misuse, 53(2), 200-205. [More Information]
  • Spaulding, A., Eldridge, G., Chico, C., Morisseau, N., Drobeniuc, A., Fils-Aime, R., Day, C., Hopkins, R., Jin, X., Chen, J., et al (2018). Smoking in Correctional Settings Worldwide: Prevalence, Bans, and Interventions. Epidemiologic Reviews, 40(1), 82-95. [More Information]
  • Day, C., Coupland, H., Moensted, M., Burns, L. (2018). The need for more research and considered debate regarding women's only treatment services: a comment on Neale et al 2018. Addiction, 113(9), 1752. [More Information]
  • Reid, S., Day, C., Bowen, D., Minnis, J., Ludlow, J., Jacobs, S., Gordon, A., Haber, P. (2018). Vertical transmission of hepatitis C: Testing and health-care engagement. Journal of Paediatrics and Child Health, 54(6), 647-652. [More Information]

2017

  • Fortier, E., Alavi, M., Bruneau, J., Micallef, M., Perram, J., Sockalingam, S., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Haber, P., et al (2017). Depression, Anxiety, and Stress among People with Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 11(1), 10-18. [More Information]
  • Larney, S., Hickman, M., Guy, R., Grebely, J., Dore, G., Gray, R., Day, C., Kimber, J., Degenhardt, L. (2017). Estimating the number of people who inject drugs in Australia. BMC Public Health, 17(757), 1-7. [More Information]
  • Butler, K., Day, C., Sutherland, R., van Buskirk, J., Breen, C., Burns, L., Larney, S. (2017). Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. International Journal of Drug Policy, 47, 102-106. [More Information]

2016

  • Al-Ansari, B., Day, C., Thow, A., Conigrave, K. (2016). Civil alcohol policy in Muslim majority countries: need for global tools, expert support and local partnerships. Addiction, 111(10), 1718-1719. [More Information]
  • White, B., Haber, P., Day, C. (2016). Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia. International Journal of Drug Policy, 27, 121-126. [More Information]
  • Day, C., Shanahan, M., Wand, H., Topp, L., Haber, P., Rodgers, C., Deacon, R., Walsh, N., Kaldor, J., Van Beek, I., et al (2016). Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. Journal Of Clinical Virology, 74, 66-72. [More Information]
  • Al-Ansari, B., Thow, A., Day, C., Conigrave, K. (2016). Extent of alcohol prohibition in civil policy in Muslim majority countries: the impact of globalization. Addiction, 111(10), 1703-1713. [More Information]
  • Mitchell, S., Bungay, V., Day, C., Mooney-Somers, J. (2016). Has the experience of Hepatitis C diagnosis improved over the last decade? An analysis of Canadian women's experiences. The Canadian Journal of Nursing Research, 48(1), 21-28. [More Information]
  • Black, K., Day, C. (2016). Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy Among Women with Substance Use Disorders. Substance Abuse: Research and Treatment, 10(Suppl. 1), 27-33. [More Information]
  • Heyes, C., Schofield, T., Gribble, R., Day, C., Haber, P. (2016). Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study. Transplantation Direct, 2(10), 1-9. [More Information]
  • Day, C., White, B., Haber, P. (2016). The impact of an automatic syringe dispensing machine in inner-city Sydney, Australia: No evidence of a 'honey-pot' effect. Drug and Alcohol Review, 35(5), 637-643. [More Information]
  • Stirling, R., Day, C. (2016). The policy and practices of New South Wales drug treatment providers in responding to the possession of illicit substances on premises. Drug and Alcohol Review, 35(5), 644-649. [More Information]
  • Grebely, J., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Phung, N., Weltman, M., Day, C., Treloar, C., Bath, N., Haber, P., et al (2016). Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study. Addiction, 111(2), 311-319. [More Information]

2015

  • Keats, J., Micallef, M., Grebely, J., Hazelwood, S., Everingham, H., Hazelwood, S., Jones, T., Bath, N., Treloar, C., Dore, G., et al (2015). Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy, 26(10), 999-1006. [More Information]
  • Alavi, M., Micallef, M., Fortier, E., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G., et al (2015). Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study. Journal of Viral Hepatitis, 22(11), 914-925. [More Information]
  • Treloar, C., Rance, J., Bath, N., Everingham, H., Micallef, M., Day, C., Hazelwood, S., Grebely, J., Dore, G. (2015). Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy, 26(10), 992-998. [More Information]
  • Haber, P., Day, C., Topp, L., Shanahan, M., Wand, H., van Beek, I., Maher, L. (2015). Hepatitis B vaccination for people who inject drugs. The Lancet, 385(9963), 115. [More Information]
  • Alavi, M., Spelman, T., Matthews, G., Haber, P., Day, C., Van Beek, I., Walsh, N., Yeung, B., Bruneau, J., Petoumenos, K., et al (2015). Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 26(10), 976-983. [More Information]
  • Fowler, C., Rossiter, C., Sherwood, J., Day, C. (2015). New Understandings of Mothering: Mothers in an Abstinence-Based Drug Treatment Program. International Journal of Mental Health and Addiction, 13(2), 173-184. [More Information]
  • Day, C. (2015). Public health responses to drug and alcohol use. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), Addiction Medicine: Principles and Practice, (pp. 36-47). Melbourne: IP Communications.
  • Bui, J., Day, C., Hanrahan, J., Winstock, A., Chaar, B. (2015). Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. Drug and Alcohol Review, 34(5), 495-498. [More Information]
  • Fortier, E., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G., et al (2015). The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 26(11), 1094-1102. [More Information]
  • Butler, K., Day, C., Dietze, P., Bruno, R., Alati, R., Burns, L. (2015). The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia. Journal of Substance Abuse Treatment, 58, 90-94. [More Information]
  • Reid, S., Day, C. (2015). Women and drugs. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), Addiction Medicine: Principles and Practice, (pp. 379-387). Melbourne: IP Communications.

2014

  • Fowler, C., Reid, S., Minnis, J., Day, C. (2014). Experiences of mothers with substance dependence: Informing the development of parenting support. Journal of Clinical Nursing, 23(19-20), 2835-2843. [More Information]
  • Deacon, R., Hines, S., Curry, K., Tynan, M., Day, C. (2014). Feasibility of ambulatory withdrawal management delivered in a NSW drug health service and correlates of completion. Australian Health Review, 38(2), 186-189. [More Information]
  • Shand, F., Day, C., Rawlinson, W., Degenhardt, L., Martin, N., Nelson, E. (2014). Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. Australian and New Zealand Journal of Public Health, 38(2), 160-164. [More Information]
  • Haber, P., Day, C. (2014). Overview of Substance Use and Treatment from Australia. Substance Abuse, 35(3), 304-308. [More Information]
  • Islam, M., Conigrave, K., Day, C., Nguyen, Y., Haber, P. (2014). Twenty-year trends in benzodiazepine dispensing in the Australian population. Internal Medicine Journal, 44(1), 57-64. [More Information]

2013

  • Topp, L., Day, C., Wand, H., Deacon, R., Van Beek, I., Haber, P., Shanahan, M., Rodgers, C., Maher, L. (2013). A randomised controlled trial of �?nancial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine, 57(4), 297-303. [More Information]
  • Islam, M., Topp, L., Conigrave, K., White, A., Haber, P., Day, C. (2013). Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. International Journal of Drug Policy, 24(4), 326-332. [More Information]
  • Alavi, M., Grebely, J., Micallef, M., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G. (2013). Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. Clinical Infectious Diseases, 57(Suppl 2), S62-S69. [More Information]
  • Md Mofizul, M., Topp, L., Conigrave, K., Day, C. (2013). De�?ning a service for people who use drugs as 'low-threshold': What should be the criteria? International Journal of Drug Policy, 24(3), 220-222. [More Information]
  • Chaar, B., Wang, H., Day, C., Hanrahan, J., Winstock, A., Fois, R. (2013). Factors influencing pharmacy services in opioid substitution treatment. Drug and Alcohol Review, 32(4), 426-434. [More Information]
  • Islam, M., Taylor, A., Smyth, C., Day, C. (2013). General health of opioid substitution therapy clients. Internal Medicine Journal, 43(12), 1335-1338. [More Information]
  • Islam, M., Topp, L., Iversen, J., Day, C., Conigrave, K., Maher, L. (2013). Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs. Australian and New Zealand Journal of Public Health, 37(2), 148-154. [More Information]
  • Islam, M., Topp, L., Conigrave, K., Day, C. (2013). Opioid substitution therapy clients' preferences for targeted versus general primary health-care outlets. Drug and Alcohol Review, 32(2), 211-214. [More Information]
  • Topp, L., Islam, M., Day, C. (2013). Relative efficacy of cash versus vouchers in engaging opioid substitution treatment clients in survey-based research. Journal of Medical Ethics, 39(4), 253-256. [More Information]
  • Mofizul Islam, M., Day, C., Conigrave, K., Topp, L. (2013). Self-perceived problem with alcohol use among opioid substitution treatment clients. Addictive Behaviors, 38(4), 2018-2021. [More Information]
  • Islam, M., Topp, L., Conigrave, K., Haber, P., White, A., Day, C. (2013). Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Australian and New Zealand Journal of Public Health, 37(4), 311-315. [More Information]
  • Islam, M., Shanahan, M., Topp, L., Conigrave, K., White, A., Day, C. (2013). The cost of providing primary health-care services from a needle and syringe program: A case study. Drug and Alcohol Review, 32(3), 312-319. [More Information]

2012

  • Deacon, R., Topp, L., Wand, H., Day, C., Rodgers, C., Haber, P., van Beek, I., Maher, L. (2012). Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. Journal of Urban Health, 89(5), 769-778. [More Information]
  • Alavi, M., Grebely, J., Matthews, G., Petoumenos, K., Yeung, B., Day, C., Lloyd, A., van Beek, I., Kaldor, J., Hellard, M., Haber, P., et al (2012). Effect of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 27(5), 957-965. [More Information]
  • Day, C., Demirkol, A., Tynan, M., Curry, K., Hines, S., Lintzeris, N., Haber, P. (2012). Individual versus team-based case-management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 31(4), 499-506. [More Information]
  • Islam, M., Topp, L., Conigrave, K., White, A., Reid, S., Grummett, S., Haber, P., Day, C. (2012). Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment, 43(4), 440-445. [More Information]
  • Mofizul Islam, M., Topp, L., Day, C., Dawson, A., Conigrave, K. (2012). Primary healthcare outlets that target injecting drug users: Opportunity to make services accessible and acceptable to the target group. International Journal of Drug Policy, 23(2), 109-110. [More Information]
  • Mofizul Islam, M., Topp, L., Day, C., Dawson, A., Conigrave, K. (2012). The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: A narrative synthesis of literature. International Journal of Drug Policy, 23(2), 94-102. [More Information]
  • Islam, M., Topp, L., Conigrave, K., van Beek, I., Maher, L., White, A., Rodgers, C., Day, C. (2012). The reliability of sensitive information provided by injecting drug users in a clinical setting: Clinician-administered versus audio computer-assisted self-interviewing (ACASI). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 24(12), 1496-1503. [More Information]

2011

  • Mofizul Islam, M., Grummett, S., White, A., Reid, S., Day, C., Haber, P. (2011). A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. Australian and New Zealand Journal of Public Health, 35(3), 294-295. [More Information]
  • Day, C., Topp, L. (2011). Commentary on Turner et al. (2011): Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission. Addiction, 106(11), 1989-1990. [More Information]
  • Day, C., Mofizul Islam, M., White, A., Reid, S., Hayes, S., Haber, P. (2011). Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Australian Journal of Primary Health, 17(1), 10-15. [More Information]
  • Topp, L., Day, C., Iversen, J., Wand, H., Maher, L. (2011). Fifteen years of HIV surveillance among people who inject drugs: the Australian Needle and Syringe Program Survey 1995-2009. AIDS, 25(6), 835-842. [More Information]
  • Chaar, B., Hanrahan, J., Day, C. (2011). Provision of Opioid Substitution Therapy Services in Australian Pharmacies. Australasian Medical Journal, 4(4), 210-216. [More Information]

2010

  • Sanson-Fisher, R., Brand, M., Shakeshaft, A., Haber, P., Day, C., Conigrave, K., Mattick, R., Lintzeris, N., Teesson, M. (2010). Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. Drug and Alcohol Review, 29(5), 469-474. [More Information]
  • Mofizul Islam, M., Day, C., Conigrave, K. (2010). Harm reduction healthcare: From an alternative to the mainstream platform? International Journal of Drug Policy, 21(2), 131-133. [More Information]
  • Day, C., White, B., Dore, G., van Beek, I., Rodgers, C., Cunningham, P., Wodak, A., Maher, L. (2010). Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status. Drug and Alcohol Dependence, 108(40210 (1-2)), 134-137. [More Information]
  • Dunn, M., Day, C., Bruno, R., Degenhardt, L., Campbell, G. (2010). Sexual and injecting risk behaviours among regular ecstasy users. Addictive Behaviors, 35(2), 157-160. [More Information]
  • Ramasamy, P., Lintzeris, N., Sutton, Y., Taylor, H., Day, C., Haber, P. (2010). The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 105(2), 329-334. [More Information]

2009

  • Doab, A., Topp, L., Day, C., Dore, G., Maher, L. (2009). Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. Contemporary Clinical Trials, 30(5), 431-435. [More Information]
  • Day, C., Haber, P. (2009). Managing drug dependence in people with hepatitis C. In G. Dore, M. Temple-Smith, A. Lloyd (Eds.), Hepatitis C: An Expanding Perspective, (pp. 288-307). East Hawthorn, Victoria: IP Communications.
  • Topp, L., Day, C., Dore, G., Maher, L. (2009). Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review. Drug and Alcohol Review, 28(6), 669-675. [More Information]
  • Coupland, H., Day, C., Levy, M., Maher, L. (2009). Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users. Health Promotion Journal of Australia, 20(3), 234-240. [More Information]

2008

  • White, B., Day, C., Thein, H., Doab, A., Bates, A., Holden, J., van Beek, I., Maher, L. (2008). Acceptability of hepatitis C virus testing methods among injecting drug users. Drug and Alcohol Review, 27, 666-670. [More Information]
  • Conroy, E., Kimber, J., Dolan, K., Day, C. (2008). An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia. Addiction Research and Theory, 16(6), 607-617. [More Information]
  • Day, C., Topp, L., Iversen, J., Maher, L., Australian NSPs, C. (2008). Blood-borne virus prevalence and risk among steroid injectors: Results from the Australian Needle and Syringe Program Survey. Drug and Alcohol Review, 27(5), 559-561. [More Information]
  • Day, C., White, B., Thein, H., Doab, A., Dore, G., Bates, A., Holden, J., Maher, L. (2008). Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 20(1), 116-123. [More Information]
  • O'Brien, S., Day, C., Black, E., Dolan, K. (2008). Injecting drug users' understanding of hepatitis C. Addictive Behaviors, 33(12), 1602-1605. [More Information]
  • Topp, L., Iversen, J., Wand, H., Day, C., Kaldor, J., Maher, L. (2008). Representativeness of Injecting Drug Users Who Participate in HIV Surveillance: Results From Australia's Needle and Syringe Program Survey. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 47(5), 632-638. [More Information]

2007

  • White, B., Day, C., Maher, L. (2007). Self reported risk behaviour among injecting drug users: Self versus assisted questionnaire completion. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 19(3), 441-447. [More Information]

2006

  • Day, C., Degenhardt, L., Hall, W. (2006). Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review, 25(4), 307-313. [More Information]
  • Day, C., Dolan, K. (2006). Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promotion Journal of Australia, 17(1), 70-72. [More Information]
  • Day, C., Degenhardt, L., Hall, W. (2006). Documenting the heroin shortage in New South Wales. Drug and Alcohol Review, 25(4), 297-305. [More Information]
  • Degenhardt, L., Day, C., Conroy, E., Gilmour, S. (2006). Examining Links Between Cocaine Use and Street-Based Sex Work in New South Wales, Australia. Journal of Sex Research, 43(2), 107-114. [More Information]
  • Gilmour, S., Koch, I., Degenhardt, L., Day, C. (2006). Identification and quantification of change in Australian illicit drug markets. BMC Public Health, 6, 200-1-200-10. [More Information]
  • Conroy, E., Degenhardt, L., Day, C. (2006). Impact of Drug Market Changes on Substance-Using Pregnant Women in Three Key Sydney Drug Markets. Women and Health: the multidisciplinary journal of women's health issues, 44(4), 93-105. [More Information]
  • Day, C., Nassirimanesh, B., Shakeshaft, A., Dolan, K. (2006). Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduction Journal, 3, 2-1-2-5. [More Information]
  • Day, C., Conroy, E., Lowe, J., Page, J., Dolan, K. (2006). Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health, 14(3), 120-125. [More Information]
  • White, B., Day, C., Degenhardt, L., Kinner, S., Fry, C., Bruno, R., Johnston, J. (2006). Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. Drug and Alcohol Dependence, 83(3), 210-217. [More Information]
  • Degenhardt, L., Day, C., Gilmour, S., Hall, W. (2006). The "lessons" of the Australian "heroin shortage". Substance Abuse Treatment, Prevention, and Policy, 1, 11-1-11-7. [More Information]
  • Gilmour, S., Degenhardt, L., Hall, W., Day, C. (2006). Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Medical Research Methodology, 6, 16-1-16-9. [More Information]

2005

  • Degenhardt, L., Day, C., Conroy, E., Gilmour, S., Hall, W. (2005). Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage" in NSW, Australia. Drug and Alcohol Dependence, 79(3), 397-404. [More Information]
  • Degenhardt, L., Day, C., Dietze, P., Pointer, S., Conroy, E., Collins, L., Hall, W. (2005). Effects of a sustained heroin shortage in three Australian States. Addiction, 100(7), 908-920. [More Information]
  • Day, C., Ross, J., Dietze, P., Dolan, K. (2005). Initiation to heroin injecting among heroin users in Sydney, Australia: cross sectional survey. Harm Reduction Journal, 2, 2-1-2-7. [More Information]
  • Degenhardt, L., Hall, W., Day, C., Dietze, P., Collins, L., Pointer, S. (2005). Mapping the Consequences of an Unanticipated Drug Supply Change of Uncertain Origins: Response to the Commentaries. Addiction, 100(7), 930-932. [More Information]
  • Degenhardt, L., Day, C., Gilmour, S., Hall, W. (2005). Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy, 16(5), 300-307. [More Information]
  • Shakeshaft, A., Nassirimanesh, B., Day, C., Dolan, K. (2005). Perceptions of substance use, treatment options and training needs among Iranian primary care physicians. International Journal for Equity in Health, 4, 7-1-7-6. [More Information]
  • Gibson, A., Degenhardt, L., Day, C., McKetin, R. (2005). Recent trends in heroin supply to markets in Australia, the United States and Western Europe. International Journal of Drug Policy, 16(5), 293-299. [More Information]
  • Degenhardt, L., Conroy, E., Day, C., Gilmour, S., Hall, W. (2005). The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence, 79(2), 129-135. [More Information]
  • Day, C., Degenhardt, L., Gilmour, S., Hall, W. (2005). The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health, 5, 84-1-84-8. [More Information]
  • Gibson, A., Day, C., Degenhardt, L. (2005). The impact of illicit drug market changes on health agency operations in Sydney, Australia. Journal of Substance Abuse Treatment, 28(1), 35-40. [More Information]
  • Degenhardt, L., Day, C., Hall, W., Conroy, E., Gilmour, S. (2005). Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime? BMC Public Health, 5, 40-1-40-10. [More Information]
  • Southgate, E., Weatherall, A., Day, C., Dolan, K. (2005). What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal for Equity in Health, 4, 5-1-5-6. [More Information]

2004

  • Day, C., Degenhardt, L., Gilmour, S., Hall, W. (2004). Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes. BMJ: British Medical Journal, 329(7463), 428-429. [More Information]
  • Day, C., Jayasuriya, R., Stone, G. (2004). Hepatitis C-related discriminationin New South Wales. Australian Health Review, 27(2), 57-60.
  • Day, C., Collins, L., Degenhardt, L., Thetford, C., Maher, L. (2004). Reliability of Heroin Users' Reports of Drug Use Behaviour Using a 24-Month Timeline-Follow-Back Technique to Assess the Impact of the Australian Heroin Shortage. Addiction Research and Theory, 12(5), 433-443. [More Information]

2003

  • Lynskey, M., Day, C., Hall, W. (2003). Alcohol and other drug use disorders among older-aged people. Drug and Alcohol Review, 22(2), 125-133.
  • Topp, L., Day, C., Degenhardt, L. (2003). Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug and Alcohol Dependence, 70, 275-286. [More Information]
  • Day, C., Ross, J., Dolan, K. (2003). Characteristics of Aboriginal Injecting Drug Users in Sydney, Australia: Prison History, Hepatitis C Status and Drug Treatment Experiences. Journal of Ethnicity in Substance Abuse, 2(3), 51-58. [More Information]
  • Topp, L., Degenhardt, L., Day, C., Collins, L. (2003). Contemplating drug monitoring systems in the light of Australia's "heroin shortage" [Editorial]. Drug and Alcohol Review, 22(1), 3-6. [More Information]
  • Day, C., Topp, L., Rouen, D., Darke, S., Hall, W., Dolan, K. (2003). Decreased heroin availability in Sydney in early 2001. Addiction, 98(1), 93-95. [More Information]
  • Day, C., Ross, J., Dolan, K. (2003). Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug and Alcohol Review, 22(3), 317-321. [More Information]
  • Degenhardt, L., Topp, L., Day, C. (2003). Issues surrounding the detection of a reduction in drug supply: the heroin shortage in Australia in 2001. United Nations. Bulletin on Narcotics, 55(1-2), 131-140.
  • Day, C., White, B., Ross, J., Dolan, K. (2003). Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney [Letter]. Australian and New Zealand Journal of Public Health, 27(5), 558.
  • Day, C., Topp, L. (2003). Safety in drug and alcohol research [Editorial]. Addiction, 98(12), 1641-1643. [More Information]

To update your profile click here. For support on your academic profile contact .